Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ANAPTYSBIO, INC (ANAB)

AnaptysBio files IRS Form 8937 on First Tracks spin-off dividend tax treatment

Neutral Impact 1 of 5 shareholder Written later

AnaptysBio has filed IRS Form 8937 and will post the same information on its website. The form covers tax treatment of the dividend stockholders received from the spin-off of First Tracks Biotherapeutics, and how the change in tax basis is determined. The filing is informational and the company urges stockholders to consult their own tax advisors.

Key points

  • AnaptysBio filed Form 8937 with the IRS, dated May 29, 2026.
  • The form describes the dividend stockholders received from the separation and spin-off of First Tracks Biotherapeutics, Inc.
  • The form explains how the dividend is treated for stockholders and how the change in tax basis is determined.
  • The company says the information is for informational purposes only and is not legal or tax advice.

The filing

CompanyANAPTYSBIO, INC (ANAB)
Form8-K, current report
Filed with the SECMay 29, 2026, 4:15 PM ET
Accession number0001193125-26-248326

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.